Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Validation of Tie2 as the First Tumour Vascular Response Biomarker for VEGF Inhibitors: Optimising the Design of a Subsequent Randomised Discontinuation Trial: VALTIVE1

NCT04523116 is registered in ClinicalTrials.gov with University of Manchester as lead sponsor.

NCT NCT04523116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04523116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Validation of Tie2 as the First Tumour Vascular Response Biomarker for VEGF Inhibitors: Optimising the Design of a Subsequent Randomised Discontinuation Trial: VALTIVE1
Lead sponsor
University of Manchester
Phase
Observational
Overall status
Unknown status
Start date
January 14, 2021
Completion date
June 30, 2023
Enrollment
176 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ovary cancer